You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it. In addition as per local health authority Regulations, some of our products are not approved for sales, marketing or distribution in all countries.
NEWS / CORPORATE / .........

CORPORATE - 04-10-2019

Kedrion submits to FDA for Manufacture of RhoGAM/MICRhoGAM in Melville, NY

On Sep 30, 2019 Kedrion Biopharma Inc. (Kedrion Biopharma) met another milestone towards transferring the drug manufacture of RhoGAM/MICRhoGAM from Ortho Clinical Diagnostics (OCD), Raritan, NJ to Kedrion Biopharma’s Melville, NY facility. A robust Prior Approval Supplement (PAS) package was submitted and acknowledged by the FDA for review. The Prescription Drug User Fee Act (PDUFA) timelines for review and approval are typically 4 months from the date of acknowledgement of the PAS submission.

This is in addition to the already FDA approved fill and finish activities for products transferred from OCD to Kedrion Biopharma in March 2019.

With the potential approval of the transfer of the drug manufacturing by early 1st Qtr 2020, Kedrion Biopharma shall be licensed to manufacture, fill, finish and label the two products at our Kedrion Biopharma Melville, NY facility.

For more information please contact: [email protected]